- Home
- ZNTL vs ELDN Comparison
ZNTL vs ELDN Comparison
Compare ZNTL & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | ELDN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 208.6M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | ELDN |
|---|---|---|
| Price | $2.49 | $2.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $6.60 | ★ $8.50 |
| AVG Volume (30 Days) | 623.6K | ★ 632.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.87 | ★ 54.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,425,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.35 |
| 52 Week High | $3.95 | $4.60 |
Technical Indicators
Market Signals| Indicator | ZNTL | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 72.32 |
| Support Level | $1.27 | $2.59 |
| Resistance Level | $2.69 | $2.77 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 55.17 | 92.41 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.